Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IL2 | P60568 | 12/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234315 | 0.99 | MEN1 (0.52) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL12093752 | 0.81 | IL2 (0.57) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL8184337 | 0.80 | IL2 (0.46) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL1828207 | 0.78 | IL2 (0.63) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL4770059 | 0.77 | IL2 (0.62) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL8193723 | 0.76 | TYK2 (0.62) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL4762822 | 0.75 | IL2 (0.60) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL2727569 | 0.74 | IL2 (0.59) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL4762638 | 0.73 | IL2 (0.58) | MEN1KMT2AIL2TNFSTIM1 | |
| SCHEMBL4769885 | 0.73 | IL2 (0.65) | MEN1KMT2AIL2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | disclosed |
| US-8729069-B2 | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-1984337-B1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | MEN1 4680/4885KMT2A 3073/4885IL2 167/4885 |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | MEN1 4680/4885KMT2A 3073/4885IL2 167/4885 |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | IL4, IL5, IL2 | MEN1 2153/4885KMT2A 1119/4885IL2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.